Four cancer drugs have got the FDA nod in May thus far, with approvals spanning haematological and solid tumour indications.

Coya Therapeutics has received fast track designation from the US FDA for COYA 302, an investigational biologic combination therapy to treat ALS.

Cellular Intelligence has licensed Novo Nordisk’s cell therapy programme for Parkinson’s disease, seven months after the Danish drugmaker wound down operations with the modality. Cellular Intelligence ...

Kyowa Kirin has received approval from the FDA for a dosing update to the Crysvita prescribing information, introducing a new option for adults with XLH.

BMS and Hengrui will trade the greater Chinese and US rights to certain programmes, while joining forces to progress five innovative assets.

Isomorphic Labs has secured $2.1bn in funding to expedite its transition from developing AI models to deploying them on a larger scale.

Hundreds of biopharma leaders say Dr Richard Pazdur has the necessary qualities to lead the FDA amid a crisis of confidence.

Pfizer has received EC approval to expand the Hympavzi indication to treat haemophilia A or B with inhibitors in patients aged 12 years and over.

Arna Pharma and Slate Run Pharmaceuticals have completed a JV to form a company focusing on branded products and 505(b)(2) medicines.

AstraZeneca’s Imfinzi (durvalumab) will become the first immunotherapy available for UK National Health Service (NHS) patients with an aggressive form of stomach cancer, after a ...

During ECO 2026, a study was presented analysing the use of tirzepatide, a dual GIP and GLP-1 agonist, in treating type 1 diabetes (T1D).

Following news that started brewing last week, Dr Marty Makary has officially resigned from his post as commissioner of the US Food and Drug Administration (FDA), with Kyle Diaman ...